Product analysis
ATP Cofactors offers reasonable value for its B-vitamin combination, but a cardiovascular benefit from its particular niacin preparation is not established.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality60
The niacin preparation is clearly identified, while the riboflavin form is less clearly disclosed. Naming the niacin form helps distinguish it from preparations with different effects.
Ingredient Transparency81
Ingredient amounts are disclosed and some forms are identified. Unspecified forms still limit like-for-like comparisons.
Value For Money70
The riboflavin comparison is competitive and the niacin comparison is reasonable. Together they support fair value for the ingredients provided.
Customer Satisfaction84
Customer feedback is strongly positive. A large review pool gives a broad view of satisfaction, though reviews do not establish health benefits.
Product Focus0
The formula is simple, but support for the cardiovascular purpose considered here is not established. That uncertainty does not show that the ingredients are clinically ineffective.
- Format
Tablet - Container
- 90 Tablet(s)
- Per serving
- $0.38
- Customer rating
- 4.8 · 1,123 ratings
Goals
ATP Cofactors lists 500 mg of inositol hexanicotinate under niacin, but this preparation has no credited contribution to the cardiovascular markers considered here. Riboflavin is also listed, yet no target pathway receives support from a credited ingredient. That lack of credited support does not establish that the preparation is clinically ineffective.
How this product is rated for Cardiovascular Support
Ingredient fit28
Goal fit
Dose adequacy
Pathways0
Depth
Breadth
Evidence0
Evidence strength
Studied preparation
Formulation logic35
Partner coverage
Conflicts
Effective doses
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
Riboflavin | 100 mg | |
Niacin (Inositol Hexanicotinate) | 500 mg |
How this ingredient is rated
Active Ingredient Quality & Bioavailability57
Niacin Form & Goal Alignment
Precursor Source Quality
Dose, Safety & Label Transparency67
Clarity of Chemical Form
Form-Specific Dosage Efficacy
Flush Risk & Safety Labeling
Value60
Price Per Effective Serving
How this ingredient is rated
Active Ingredient Quality & Bioavailability30
Riboflavin Form Quality
Dose, Safety & Label Transparency100
Dosage for Energy & Metabolism
R5P Elemental Yield Transparency
Additive Purity
Value80
Price per Serving Value
Alternative products
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression.
- Effects of niacin on apo A1 and B levels: a systematic review and meta-analysis of randomised controlled trials.
- Effect of lipid-lowering therapies on lipoprotein(a) levels: a comprehensive meta-analysis of randomized controlled trials.
- Extended-release niacin vs gemfibrozil for the treatment of low levels of high-density lipoprotein cholesterol. Niaspan-Gemfibrozil Study Group.
- Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
- Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I.
- The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration.
- The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome.
- Effect of niacin therapy on cardiovascular outcomes in patients with coronary artery disease.
- Effect of niacin on endothelial function: a systematic review and meta-analysis of randomized controlled trials.